Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MT-7117 in Healthy Subjects
NCT02834442Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Jul 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dersimelagon in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) (2 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoints: Safety and Tolerability as measured by number of participants with adverse events, Safety and Tolerability as measured by vital signs and 3 more. Started Jul 2016; status: completed.
02
Drugs
dersimelagon
03
Conditions
erythropoietic protoporphyria (EPP)X-linked protoporphyria (XLP)
Beyond the preview
Go deeper on NCT02834442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02834442.